Stem cell transplants for patients with relapsed/refractory leukaemia

Area of Science:

• Hematology
• Immunology
• Oncology

Background:

• Allogeneic stem cell transplantation (allo-SCT) indications for high-risk leukemia in first remission are established.
• The use of allo-SCT for primary refractory leukemia, relapse, advanced disease, and elderly patients with comorbidities remains controversial.
• These patient groups often have a poor prognosis with conventional chemotherapy and transplantation.

Purpose of the Study:

• To review the current indications and outcomes of allogeneic stem cell transplantation for leukemia.
• To evaluate the role of alloimmunity and reduced-intensity conditioning in improving transplant success.
• To assess the applicability of allo-SCT in challenging patient populations, including the elderly and those with advanced disease.

Main Methods:

• Review of existing literature on allogeneic stem cell transplantation for leukemia.
• Analysis of the impact of reduced-intensity conditioning regimens and nonmyeloablative protocols.
• Evaluation of graft-versus-leukemia reactions and the role of donor immune repertoire.

Main Results:

• Reduced-intensity conditioning and nonmyeloablative regimens enable allo-SCT for elderly patients and those with acute myeloid leukemia and myelodysplastic syndromes.
• Graft-versus-leukemia reactions, demonstrated by donor lymphocyte infusions, are crucial for leukemia control.
• Antibody-based therapies and double cord blood transplants have improved outcomes in lymphoid malignancies.

Conclusions:

• Allogeneic stem cell transplantation, utilizing alloimmune reactions and reduced-intensity conditioning, is now feasible and successful in elderly and fragile leukemia patients.
• Combining molecular monitoring, targeted therapies, and transplantation as immunotherapy holds promise for further improving leukemia treatment outcomes.